Literature DB >> 16784024

Heat shock protein-90 inhibitors: a chronicle from geldanamycin to today's agents.

Gabriela Chiosis1, Eloisi Caldas Lopes, David Solit.   

Abstract

Heat shock protein (Hsp)90 is a chaperone with essential roles in maintaining transformation and in elevating the survival and growth potential of cancer cells. The recognition of Hsp90 as an important target in cancer therapy has prompted the identification, development and clinical translation of a large array of Hsp90 inhibitors. This review discusses the modalities that may interfere with this chaperone's function and describes the status of existing and emerging Hsp90 inhibitor classes.

Entities:  

Mesh：

Substances：

Year:  2006        PMID： 16784024

Source DB:  PubMed          Journal:  Curr Opin Investig Drugs        ISSN： 1472-4472


  32 in total

Review 1.  Heat shock proteins and kidney disease: perspectives of HSP therapy.

Authors:  Natalia Chebotareva; Irina Bobkova; Evgeniy Shilov
Journal:  Cell Stress Chaperones       Date:  2017-04-13       Impact factor: 3.667

2.  Microwave-assisted one step synthesis of 8-arylmethyl-9H-purin-6-amines.

Authors:  Hui Tao; Yanlong Kang; Tony Taldone; Gabriela Chiosis
Journal:  Bioorg Med Chem Lett       Date:  2008-11-20       Impact factor: 2.823

3.  A purine scaffold HSP90 inhibitor BIIB021 has selective activity against KSHV-associated primary effusion lymphoma and blocks vFLIP K13-induced NF-κB.

Authors:  Ramakrishnan Gopalakrishnan; Hittu Matta; Preet M Chaudhary
Journal:  Clin Cancer Res       Date:  2013-07-23       Impact factor: 12.531

4.  Divergent synthesis of a pochonin library targeting HSP90 and in vivo efficacy of an identified inhibitor.

Authors:  Sofia Barluenga; Cuihua Wang; Jean-Gonzague Fontaine; Kaïss Aouadi; Kristin Beebe; Shinji Tsutsumi; Len Neckers; Nicolas Winssinger
Journal:  Angew Chem Int Ed Engl       Date:  2008       Impact factor: 15.336

5.  Syntheses and discovery of a novel class of cinnamic hydroxamates as histone deacetylase inhibitors by multimodality molecular imaging in living subjects.

Authors:  C T Chan; J Qi; W Smith; R Paranol; R Mazitschek; N West; R Reeves; G Chiosis; S L Schreiber; J E Bradner; R Paulmurugan; S S Gambhir
Journal:  Cancer Res       Date:  2014-10-15       Impact factor: 12.701

6.  PU-H71 effectively induces degradation of IκB kinase β in the presence of TNF-α.

Authors:  Zhuling Qu; Shiduan Wang; Ruyang Teng; Xuanlong Yi
Journal:  Mol Cell Biochem       Date:  2013-10-10       Impact factor: 3.396

7.  Anti-malaria drug blocks proteotoxic stress response: anti-cancer implications.

Authors:  Nickolay Neznanov; Anton V Gorbachev; Lubov Neznanova; Andrei P Komarov; Katerina V Gurova; Alexander V Gasparian; Amiya K Banerjee; Alexandru Almasan; Robert L Fairchild; Andrei V Gudkov
Journal:  Cell Cycle       Date:  2009-12-25       Impact factor: 4.534

8.  Dynamics of conserved waters in human Hsp90: implications for drug design.

Authors:  Aixia Yan; Guy H Grant; W Graham Richards
Journal:  J R Soc Interface       Date:  2008-12-06       Impact factor: 4.118

Review 9.  Histone deacetylase inhibitors: the epigenetic therapeutics that repress hypoxia-inducible factors.

Authors:  Shuyang Chen; Nianli Sang
Journal:  J Biomed Biotechnol       Date:  2010-12-05

10.  The anti-myeloma activity of a novel purine scaffold HSP90 inhibitor PU-H71 is via inhibition of both HSP90A and HSP90B1.

Authors:  Saad Z Usmani; Robert D Bona; Gabriela Chiosis; Zihai Li
Journal:  J Hematol Oncol       Date:  2010-10-26       Impact factor: 17.388
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.